Arbutus Biopharma Corp (NASDAQ: ABUS) on Monday, plunged -6.04% from the previous trading day, before settling in for the closing price of $3.31. Within the past 52 weeks, ABUS’s price has moved between $2.30 and $4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 68.89% over the past five years. The company achieved an average annual earnings per share of 12.50%. With a float of $147.08 million, this company’s outstanding shares have now reached $189.44 million.
Let’s look at the performance matrix of the company that is accounted for 73 employees. In terms of profitability, gross margin is 84.13%, operating margin of -1223.89%, and the pretax margin is -1137.64%.
Arbutus Biopharma Corp (ABUS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arbutus Biopharma Corp is 22.38%, while institutional ownership is 54.97%. The most recent insider transaction that took place on Mar 07 ’25, was worth 549,963. Before that another transaction happened on Feb 04 ’25, when Company’s Chief Financial Officer sold 22,183 for $3.28, making the entire transaction worth $72,827. This insider now owns 159,724 shares in total.
Arbutus Biopharma Corp (ABUS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.50% per share during the next fiscal year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Arbutus Biopharma Corp (ABUS) is currently performing well based on its current performance indicators. A quick ratio of 7.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 87.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.30 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ: ABUS) saw its 5-day average volume 1.1 million, a positive change from its year-to-date volume of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 12.93%. Additionally, its Average True Range was 0.16.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 1.59%, which indicates a significant decrease from 3.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.70% in the past 14 days, which was lower than the 41.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.33, while its 200-day Moving Average is $3.59. Nevertheless, the first resistance level for the watch stands at $3.26 in the near term. At $3.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.49. If the price goes on to break the first support level at $3.03, it is likely to go to the next support level at $2.94. Assuming the price breaks the second support level, the third support level stands at $2.79.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
Market capitalization of the company is 589.32 million based on 189,492K outstanding shares. Right now, sales total 18,140 K and income totals -72,850 K. The company made 1,340 K in profit during its latest quarter, and -19,720 K in sales during its previous quarter.
